Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

VJVirtual | Checkpoint blockade in PS2 NSCLC patients

Sanjay Popat • 15 May 2020
Lung Cancer Non-Small Cell Lung Cancer Nivolumab Pembrolizumab
CheckMate 171 PePS2

Sanjay Popat, BSc, MBBS, FRCP, PhD, The Royal Marsden NHS Foundation Trust, London, UK, discusses the results of the Checkmate 171 (NCT02409368) and PePS2 (NCT02733159) studies which have highlighted a significant benefit of checkpoint blockade therapy for advanced non-small cell lung cancer (NSCLC) patients. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Sanjay Popat

0:34
VJOncology at BTOG 2023
Sanjay Popat • 28 Apr 2023
0:34
VJOncology at BTOG 2023
Sanjay Popat • 28 Apr 2023
1:21
SYSTEMS-2: Radiotherapy and potential survival benefits in mesothelioma
Sanjay Popat • 29 Apr 2023
2:18
Highlights from BTOG 2023
Sanjay Popat • 28 Apr 2023

Related Videos

1:03
The benefits of liquid biopsies for lung cancer in the community setting
Deepti Behl • 9 Apr 2024
0:57
STK-012-101: STK-012 in advanced solid tumors
Alexander Spira • 15 Mar 2024
3:34
FLAURA2: EGFRm dynamics in NSCLC treated with osimertinib
Pasi Jänne • 8 Apr 2024
0:54
FURVENT: furmonertinib in EGFR exon 20 mutant NSCLC
Alexander Spira • 15 Mar 2024
The content of VJOncology is intended for healthcare professionals